Ezrin is an Essential Marker for Metastasis of Gynecologic Cancer

키워드

참고문헌 (40)

1. Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
2. United States Cancer Statistics: 2004 Incidence and Mortality, "U.S. Cancer Statistics Working Group", Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, ~ (2007)
3. Buda A, "Role of ifosfamide in cervical cancer : an overview", Oncology, 65(Suppl 2), pp.63~66 (2003)
4. Lee CJ, "Conventional and proteomic technologies for the detection of early stage malignancies : markers for ovarian cancer", Crit Rev Clin Lab Sci, 44, pp.87~114 (2007)
5. Mehlen P, "Metastasis : a question of life or death", Nat Rev Cancer, 6, pp.449~458 (2006)
6. Bretscher A, "ERM proteins and merlin : integrators at the cell cortex", Nat Rev Mol Cell Biol, 3, pp.586~599 (2002)
7. Curto M, "Ezrin...a metastatic detERMinant?", Cancer Cell, 5, pp.113~114 (2004)
8. Martin TA, "The role of the CD44", ezrin complex in cancer metastasis, 2003, pp.46, 165~186
9. Fazioli F, "The ezrin-like family of tyrosine kinase substrates : receptor-specific pattern of tyrosine phosphorylation and relationship to malignant transformation", Oncogene, 8, pp.1335~1345 (1993)
10. Ohtani K, "Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma", Cancer Lett, 179, pp.79~86 (2002)
11. Bruce B, "Expression of the cytoskeleton linker protein ezrin in human cancers", Clin Exp Metastasis, 24, pp.69~78 (2007)
12. Chen Z, "Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor", Cancer, 92, pp.3068~3075 (2001)
13. Köbel M, "Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas", Mod Pathol, 19, pp.581~587 (2006)
14. Khanna C, "The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis", Nat Med, 10, pp.182~186 (2004)
15. Bretscher A, "Soluble ezrin purified from placenta exists as stable monomers and elongated dimers with masked C-terminal ezrin-radixin-moesin association domains", Biochemistry (Mosc), 34, pp.16830~16837 (1995)
16. Frixione E, "Recurring views on the structure and function of the cytoskeleton : a 300-year epic", Cell Motil Cytoskeleton, 46, pp.73~94 (2000)
17. Doherty GJ, "Mediation, modulation, and consequences of membrane-cytoskeleton interactions", Annu Rev Biophys, 37, pp.65~95 (2008)
18. Friedl P, "Tumour-cell invasion and migration: diversity and escape mechanisms", Nat Rev Cancer, 3, pp.362~374 (2003)
19. Yonemura S, "Direct involvement of ezrin", radixin, J Cell Biol, pp.1999, 145[DOI]
20. Lesley J, "CD44 and its interaction with extracellular matrix", Adv Immunol, 54, pp.271~335 (1993)
21. Rodríguez-Rodríguez L, "CD44 splice variant expression in clear cell carcinoma of the ovary", Gynecol Oncol, 71, pp.223~229 (1998)
22. Springer TA, "Adhesion receptors of the immune system", Nature, 346, pp.425~434 (1990)
23. Arnold JM, "Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas", Br J Cancer, 85, pp.1351~1358 (2001)
24. Helander TS, "ICAM-2 redistributed by ezrin as a target for killer cells", Nature, 382, pp.265~268 (1996)
25. Reczek D, "Identification of EBP50: a PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family", J Cell Biol, 139, pp.169~179 (1997)
26. Smith PM, "Tissuespecific regulation by estrogen of ezrin and ezrin", radixin, Endocrine, pp.2003, 22[DOI]
27. Georgescu MM, "Roles of NHERF1", EBP50 in cancer, 2008, pp.8, 459~468
28. Crepaldi T, "Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells", J Cell Biol, 138, pp.423~434 (1997)
29. Kondo T, "ERM (ezrin", radixin, J Cell Biol, pp.1997, 139[DOI]
30. Hirao M, "Regulation mechanism of ERM (ezrin", radixin, plasma membrane association: possible involvement of phosphatidylinositol turnover and Rhodependent signaling pathway, pp.J Cell Biol, 1996[DOI]
31. Barret C, "Mutagenesis of the phosphatidylinositol 4,5-bisphosphate (PIP(2)) binding site in the NH(2)-terminal domain of ezrin correlates with its altered cellular distribution", J Cell Biol, 151, pp.1067~1080 (2000)
32. Karlsson R, "Rho GTPase function in tumorigenesis", Biochim Biophys Acta, 1796, pp.91~98 (2009)
33. del Peso L, "Rho proteins induce metastatic properties in vivo", Oncogene, 15, pp.3047~3057 (1997)
34. Tsai MH, "Rho-kinase-mediated regulation of receptor-agonist-stimulated smooth muscle contraction", Pflugers Arch, 453, pp.223~232 (2006)
35. Takahashi K, "Direct interaction of the Rho GDP dissociation inhibitor with ezrin", radixin, J Biol Chem, pp.1997, 272[DOI]
36. Smith PM, "Reciprocal regulation by estradiol 17-beta of ezrin and cadherin-catenin complexes in pituitary GH3 cells", Endocrine, 17, pp.219~228 (2002)
37. Stemmer-Rachamimov AO, "NHERF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas", Am J Pathol, 158, pp.57~62 (2001)
38. Ohtani K, "Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells", Cancer Lett, 147, pp.31~38 (1999)
39. Song J, "Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen", Cancer Lett, 220, pp.57~65 (2005)
40. Weiss L, "Metastasis of cancer: a conceptual history from antiquity to the 1990s", Cancer Metastasis Rev, 19, pp.193~383 (2000)

관련 논문AI추천